FILTER

FILTERED INTERVIEW RESULTS

Manni Kantipudi & Ramesh Subramanian

CHIEF EXECUTIVE OFFICER (MK) & CHIEF COMMERCIAL OFFICER (RS), ARAGEN LIFE SCIENCES
"Overall, I believe the virtual biotech model is here to stay and companies will increasingly look at CRO/CDMO companies for assistance in taking drugs from discovery to commercialization."

Chris Garabedian

CHAIRMAN AND CEO, XONTOGENY, AND PORTFOLIO MANAGER, PERCEPTIVE XONTOGENY VENTURE (PXV) FUND
"Following a long period of significant investment in early-stage firms, our industry needs to allow existing investments across the industry to mature and show signs of success before driving new investments in preclinical-stage projects."

Tom Wilson

GLOBAL BUSINESS DEVELOPMENT LEAD, PFIZER CENTREONE
"As we get into precision medicines, therapies, parallel trials, and getting medicines to patients faster, that will require CDMOs to work together, and this is where our growth will come from."

Fabrice Panza

MANAGER GLOBAL COOL CHAIN SOLUTIONS, ETIHAD CARGO
"Etihad Cargo’s PharmaLife product has exponentially grown over the past year, and growth will trigger more physical ties between US and UAE."

James Sapirstein

CHAIRMAN, PRESIDENT, AND CEO, FIRST WAVE BIOPHARMA
“We are happy to report that we have initiated the Phase 2 SPAN adrulipase clinical and are currently screening patients for the study. We anticipate topline data by mid-2023.”

Kendalle O’Connell

CEO AND PRESIDENT, MASSBIO
"In 2022, Massachusetts received 25% of all biopharma VC funding in the US. We are seeing new clusters emerge outside the traditional hubs of Kendall Square and Boston."

Arda Ural

AMERICAS INDUSTRY MARKET LEADER, HEALTH SCIENCES & WELLNESS, EY USA
"We are going to help the industry digitalize, prepare for the innovation deficit due to expiring patents and improve strategies that lead to better M&A opportunities."

David Schaffer

EXECUTIVE DIRECTOR, QB3
"The Bay Area offers a confluence of universities, investors and companies, and we are interested in strengthening bridges between these institutions to streamline the process of technology translation."

Mark A. Goldberg

CEO, ALLUCENT
"Given that a significant amount of intellectual property and cutting-edge science resides within smaller companies, we created a purpose-built firm to help smaller players develop their products and bring them to market."

Gil Roth

PRESIDENT, PBOA
"The Ukraine crisis highlighted how Europe needs to look at its energy supply and how it will make sure they have secure supply chains. Part of that has involved the US more closely. Geopolitics will have a more significant impact going forward."

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS